Durvalumab vs Erlotinib

## Durvalumab vs Erlotinib: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Erlotinib**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Erlotinib**: Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Erlotinib — 36 hours.

## Chemical Properties

**Molecular Formula**: Durvalumab — N/A; Erlotinib — C22H23N3O4.

**Molecular Weight**: Durvalumab — N/A; Erlotinib — 393.4380 g/mol.

**Type**: Durvalumab — Antibody; Erlotinib — Small molecule.